Aleix Prat, Director of the Clínic Barcelona Comprehensive Cancer Center, shared on LinkedIn:
“Happy to see this comprehensive review of HER2DX in early-stage HER2+ breast cancer published in ESMO – European Society for Medical Oncology, led by Sara Tolaney and an international group of breast cancer experts.
I am not an author of this paper, but of course I have a strong connection to this work and a relevant COI through REVEAL GENOMICS and the development of HER2DX.
The review provides an updated overview of the evidence generated with HER2DX and discusses its potential clinical utility across different scenarios in early HER2+ breast cancer.
It covers the three HER2DX outputs, relapse risk, pCR likelihood and ERBB2 mRNA expression, and summarizes evidence from retrospective studies, patient-level meta-analyses, prospective studies and real-world data.
Importantly, the authors also highlight the current limitations of the evidence and the need for prospective validation of HER2DX-guided treatment strategies.
A useful and timely overview of where the evidence stands today, and of the questions that still need to be answered.
Congratulations to Sara Tolaney and all the authors.”
Title: HER2DX in early-stage HER2-positive breast cancer: a review of clinical utility
Authors: S.M. Tolaney, N. Tung, A.C. Wolff, A. DeMichele, J.M. Cejalvo, O. Martínez-Sáez, T. Pascual, A.G. Waks, K. Nozawa, H. Iwata, M. Martín, E. Ciruelos, N. Harbeck, L.A. Carey, J. Cortés, A. Llombart, P. Sharma, G. Curigliano.
Read the full article.
This also can be interesting: Can HER2DX Help Refine Neoadjuvant Treatment in Early HER2-Positive Breast Cancer?
